Partner:
Asset Type:
Partner Background:
Partnership Details:
Partner:

Asset Type:
Immuno-Oncology
Partner Background:
Yuhan Corporation is one of the largest Korean pharmaceutical companies, founded over 80 years ago
Partnership Details:
Joint Venture named ImmuneOncia Therapeutics, LLC
Focused on developing and commercializing a number of immune checkpoint antibodies for hematological malignancies and solid tumors
Partner:

Asset Type:
Immuno-Oncology
Partner Background:
Lee’s Pharm is a public biopharma company with over 20 years of operation in China and currently markets 14 products in the PRC
Partnership Details:
Sorrento has licensed exclusive rights to Lee’s Pharm to develop and commercialize the fully human anti-PD-L1 mAb STI-A1014 for the greater Chinese market
Partner:

Asset Type:
Cellular Therapy
Partner Background:
Celularity is a spin-off from Celgene Corporation focusing on placenta-derived and cord-blood derived cells therapies
Partnership Details:
Equity Investment and Board Representation
Partner:

Asset Type:
Immuno-oncology
Partner Background:
MABPHARM is a biopharma company focusing on the R&D and production of new drugs and “Biobetters” for cancer and autoimmune diseases
Partnership Details:
Sorrento has an exclusive license to commercialize four Biobetters that have completed Phase 3 studies in China for the North American, European and Japan markets
At Sorrento, we seek strong partnerships and collaborations as a critical driver of our strategy to push the boundaries of science and deliver life-changing therapies to patients so they can live healthier and happier lives.


